SciClone Pharmaceuticals, Inc. (SCLN) Scheduled to Post Quarterly Earnings on Tuesday
SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) is scheduled to be issuing its quarterly earnings data after the market closes on Tuesday, November 7th. Analysts expect the company to announce earnings of $0.22 per share for the quarter.
SciClone Pharmaceuticals (NASDAQ:SCLN) last issued its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.26 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.24 by $0.02. The company had revenue of $44.52 million during the quarter. SciClone Pharmaceuticals had a return on equity of 20.24% and a net margin of 27.39%.
SciClone Pharmaceuticals, Inc. (SCLN) opened at $11.15 on Monday. SciClone Pharmaceuticals, Inc. has a twelve month low of $8.55 and a twelve month high of $11.43.
TRADEMARK VIOLATION WARNING: “SciClone Pharmaceuticals, Inc. (SCLN) Scheduled to Post Quarterly Earnings on Tuesday” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/sciclone-pharmaceuticals-inc-scln-scheduled-to-post-quarterly-earnings-on-tuesday/1681770.html.
In other news, CEO Hong Zhao sold 30,000 shares of the company’s stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $11.00, for a total transaction of $330,000.00. Following the completion of the sale, the chief executive officer now directly owns 30,000 shares in the company, valued at approximately $330,000. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Lan Xie sold 10,000 shares of the company’s stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $11.00, for a total value of $110,000.00. Following the sale, the vice president now owns 10,000 shares of the company’s stock, valued at $110,000. The disclosure for this sale can be found here. Insiders own 5.16% of the company’s stock.
About SciClone Pharmaceuticals
SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.
Receive News & Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.